Shattuck Labs   Report issue

For profit Phase 1
Founded: Austin TX United States (2016)

Organization Overview

First Clinical Trial
2019
NCT03894618
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Shattuck Labs | Shattuck Labs, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Anus Neoplasms (Phase 1)

Carcinoma (Phase 1)

Carcinoma, Ovarian Epithelial (Phase 1)

Carcinoma, Squamous Cell (Phase 1)

Fallopian Tube Neoplasms (Phase 1)

Lymphoma (Phase 1)

Lymphoma, Large B-Cell, Diffuse (Phase 1)

Ovarian Neoplasms (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 5
  • # of Trial APIs: 4